Concurrent Computer Positive Money Flow After Cable TV Deal

April 30, 2017: Concurrent Computer’s stock has done a positive divergence on the money flow after cable TV innovator Midco chooses Concurrent’s CDN Platform to expand video on demand options for 385,000 midwest customers. Concurrent Computer announced that Sioux Falls-based telecommunications provider Midco, one of the 20 largest cable television operators in the U.S., has launched Concurrent’s full suite of CDN products including Storage, Origin and Edge. Concurrent’s CDN Platform is a comprehensive system for ingesting, hosting, distributing, and streaming video content to any device, any time, over any network.Midco serves more than 385,000 subscribers throughout Kansas, Minnesota, North Dakota, South Dakota and Wisconsin and has delivered on-demand movies and TV shows for nearly a decade. As an early innovator in VOD, Midco has mastered delivery of content to digital televisions and set-top boxes, and with Concurrent, Midco not only upgrades services for these traditional devices, it can add IP-based devices such as PCs, smartphones, and tablets.

Concurrent Computer is a high risk play and it does not meet the typical fundamental criteria I screen for.

Below is a chart of the Twiggs Money Flow so you can see the positive divergence between the money flow and price.

Concurrent is a global leader in unified content delivery, video analytics, and real-time Linux solutions. The company delivers solutions for every screen and every network in support of commercial video services. Concurrent’s unified content delivery and video analytics solutions support every screen simultaneously, making it easier for cable MSOs, fixed-line telecommunications providers, mobile operators, and online media companies to deliver revenue generating video services to consumers on any device, over any network. The world’s leading multichannel video service providers have selected Concurrent to deliver the solutions and services required to support their next-generation multi-screen video initiatives.

Concurrent’s Emmy award-winning video solutions are based upon a rich heritage of high-performance real-time technology. Concurrent’s real-time Linux solutions are used to support applications in the defense, aerospace, automotive and financial industries. Concurrent has offices in North America, Europe and Asia.

President Trump Signs Stopgap Funding To Keep Government Open Until May 5th

President Trump, on Friday, signed a Congressional stopgap funding bill to keep the government open until May 5th.

Meanwhile the mainstream media continues to ignore the fact that a government shutdown is at hand, choosing instead to bash away at Trump’s first 100 days and to run fake left-leaning Gallup polls and fake left-leaning PolitiFact blog articles. PolitiFact is owned and funded by groups with ties to the Democrat party. Here is PolitiFact stroking Nancy Pelosi: http://www.politifact.com/truth-o-meter/statements/2017/apr/28/nancy-pelosi/nancy-pelosi-target-about-what-donald-trump-might-/ Where was PolitiFact, fact checking Nancy Pelosi’s many lies like her insider trading in an IPO she favorably voted on?

Sell Anavex Life Sciences For a Huge 40% Win

April 30, 2017: Sell Anavex Life Sciences for a huge 40% win and congratulations if you made money on this trade.

January 8, 2017: Institutional traders are accumulating biotechnology firm Anavex Life Sciences according to recent 13F filings. The institutional traders who bought the most shares of Anavex Life Sciences are:

BlackRock Fund Advisors = bought 843,994 shares according to 11-11-2016 filing
BlackRock Institutional Trust = bought 284,540 shares according to 11-11-2016 filing
State Street Corp = bought 218,377 shares according to 11-14-2016 filing
Bank of New York Mellon = bought 129,276 shares according to 11-12-2016 filing
Black Rock Investment Management = bought 127,022 shares according to 11-11-2016 filing
D. E. Shaw & Co = bought 105,080 shares according to 11-14-2016 filing
SUSQUEHANNA International Group = bought 102,685 shares according to 11-14-2016 filing
GEODE CAPITAL Management = bought 46,739 shares according to 11-11-2016 filing
VANGUARD GROUP INC = bought 30,148 shares according to 11-14-2016 filing
California State Teachers Retirement System = bought 68,464 shares according to 11-11-2016 filing
NORTHERN TRUST CORP = bought 58,307 shares according to 11-12-2016 filing
TIAA CREF INVESTMENT MANAGEMENT = bought 25,129 shares according to 12-12-2016 filing

November 22, 2016: Anavex Life Sciences announces data on 41-Week treatment of ANAVEX 2-73 for patients with Alzheimer’s Disease; Investigational treatment suggests to curb cognitive and functional decline. At 41 weeks, Alzheimers patients taking a daily oral dose of ANAVEX 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimers disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and not stop the disease from progressing.

At 41 weeks, oral daily dosing between 10mg and 50mg, ANAVEX 2-73 was well tolerated, and no patients discontinued treatment due to adverse events. There were no clinically significant treatment-related adverse events, and no serious adverse events.

Pre-specified exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization of both cognitive (MMSE) and functional (ADCS-ADL) measures in patients treated with ANAVEX 2-73 was observed. This correlation was positive with all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).

About the ANAVEX 2-73 Phase 2a Study

The multicenter Phase 2a clinical trial of ANAVEX 2-73 consists of two parts and a total of 32 mild-to-moderate Alzheimers patients. PART A is a simple randomized, open-label, two-period, cross-over between oral (30mg/50mg) and IV (3mg/5mg) administration, adaptive trial lasting up to 5 weeks for each patient. PART B is an open-label extension for an additional 52 weeks. Initially planned for 26 weeks, PART B was extended to 52 weeks as a result of requests from patients and caregivers.

The primary endpoint of the Phase 2a trial is to establish safety, tolerability and maximum tolerated dose (MTD) of ANAVEX 2-73, which had shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Secondary endpoints include dose response, bioavailability, and exploratory cognitive as well as functional measures using Mini Mental State Examination (MMSE) and evaluation of Alzheimers Disease Co-operative Study Activities of Daily Living Inventory (ADCS-ADL), as well as Cogstate test battery and EEG/ERP.

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer.

Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial.

Sell Catalyst Pharmaceuticals For a 47% Gain

April 16, 2017: Sell Catalyst Pharmaceuticals for a 47% gain in 60 days and congratulations if you made money on the trade.

January 4, 2017: The popular SeekingAlpha blogger Hawkinvest, with over 5,000 followers, posted a positive article on Catalyst Pharmaceuticals today that got the stock moving higher. Hawkinvest writes

Biotech and healthcare stocks underperformed in 2016 and that means this is a sector that could offer value and rebound potential in 2017. With all of this in mind, I have been looking for “hidden gems” in the biotech sector. I have recently found a couple of very interesting investment opportunities that offer an excellent risk to reward ratio and one of the stocks I am bullish on now is Catalyst Pharmaceuticals, Inc

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which completed Phase III clinical trial for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of MuSK-antibody positive myasthenia gravis.

Sell Cancer Genetics For an Awesome 133% Win!

April 16, 2017: Sell Cancer Genetics for an incredible 133% win in 85 days and congratulations if you made money on the trade.

December 9, 2016: H.C. Wainwright/ Rodman & Renshaw reiterates a Buy rating on Cancer Genetics, and sets a price target of $6.

December 7, 2016: Cancer Genetics announced a collaboration with BeiGene, a global, clinical-stage, research-based biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The two companies will work together on BeiGenes immune marker and genomics initiatives to accelerate studies of tumor microenvironment in cancer patients, which will aid in drug target identification and biomarker discovery.

BeiGenes clinical-stage drug candidates inhibit four major oncology targets, including Brutons tyrosine kinase (BGB-3111), the immune checkpoint receptor PD-1 (BGB-A317), the PARP family of proteins (BGB-290), and the RAF dimer protein complex (BGB-283). Each of BeiGenes drug candidates has demonstrated promising early anti-tumor activity and a favorable safety profile and has the potential to be a best-in-class or first-in-class product. These drug candidates are being evaluated as monotherapies and in combination regimens for the treatment of a variety of cancers, including solid tumors and hematological malignancies. CGI will provide biomarker and central laboratory for multiple clinical trials for BeiGenes BGB-3111, BGB-A317, and BGB-290 programs to promote accelerated market entrance and identify subsets of patient populations.

December 5, 2016: Cancer Genetics announces it is on Merck’s list of national reference laboratories offering the PD-L1 22C3 pharmDx immunohistochemistry (IHC) assay, the first U.S. Food and Drug Administration (FDA)-approved companion diagnostic test for pembrolizumab, KEYTRUDA, for PD-L1 testing in non-small cell lung cancer (NSCLC). The company first started offering the DAKO PD-L1 IHC 22C3 pharmDx test in early 2016 and was recently listed as a national reference laboratory.

Cancer Genetics now offers all the available FDA approved companion diagnostics for PD-L1 testing across several cancer indications and is providing these tests for both patient management in the clinical setting as well as for immuno-oncology trials sponsored by leading pharmaceutical companies. Cancer Genetics is now supporting over 100 clinical studies and trials, and over 30 with a component for immuno-oncology testing and monitoring.

Cancer Genetics, Inc. offerers diagnostic products and services that enable precision medicine in the field of oncology. Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.

When Will Stock Market Crash

A weekly Saturday financial show that attempts to predict market direction for the week ahead by looking at a variety of fundamental and technical charts. This week’s show features commentary on the Federal Reserve raising the time table for reducing their balance sheet, the surge higher in commercial bankruptcies, the plunge in Wells Fargo’s home mortgage loans, the state of California laying off 1,750 teachers, John McCain’s insane war rants, the false flag in Syria and Trump’s missile strike, Russia’s growing anger against the United States and what it’s doing in retaliation for the unconstitutional Syria strike, Trump reversing himself on many issues that were central to his campaign, and more.

Help us spread the word about what’s really going on in the stock market and economy. We’re reaching thousands, help us reach millions by sharing this show with your family and friends.

Follow Lance on STOCKTWITS: https://stocktwits.com/lancejepsen
Follow Lance on TWITTER: https://twitter.com/lancejepsen
Follow Lance on FACEBOOK: https://www.facebook.com/GuerillaStoc…

Visit https://www.guerillastocktradingstore… to get the products Lance Jepsen and his family trust, while supporting the growth of our operations.

[http://bit.ly/2nPfkiJ] Introduction to Value Investing
[http://bit.ly/2okfmmL] How to Find Great Stock Picks
[http://bit.ly/2nPeWkw] Due Diligence: Researching a Stock
[http://bit.ly/2pfoLZV] Guide to Navigating EDGAR
[http://bit.ly/2nPd7Eh] How to Value a Company
[http://bit.ly/2nPaodT] Accounting 101: Value Investing
[http://bit.ly/2pfgOnE] Understanding the Balance Sheet
[http://bit.ly/2obtahx] Understanding the Income Statement
[http://bit.ly/2pfqeQb] Understanding the Cash Flow Statement
[http://bit.ly/2pfeugH] How to Use Financial Ratios
[http://bit.ly/2mimVL2] Cotytech Wall Mount for Four Monitors
[http://bit.ly/2mGlOQu] Cotytech Four Monitor Desk Mount Quick Release
[http://bit.ly/2nHC5GT] DS100 Quad-Monitor Desk Stand by Ergotron
[http://bit.ly/2nbELi9] DS100 Triple-Monitor Desk Stand by Ergotron
[http://bit.ly/2npHl4j] Mount-It! Quad Freestanding Monitor Stand
[http://bit.ly/2nHxQeo] MonMount Free Standing Quad/Four LCD Monitor Stand
[http://bit.ly/2nBfxuk] VIVO Dual LCD Monitor Desk Mount Stand Heavy Duty
[http://bit.ly/2mGeW5O] The Complete Guide to Technical Indicators
[http://bit.ly/2npwE1K] Unlocking the Profits of the New Swing Chart Method
[http://bit.ly/2n4V8g0] Microeconomics by Worth Publishers
[http://bit.ly/2nbHQ1m] Principles of Macroeconomics (Mankiw’s Principles)
[http://bit.ly/2mGb30D] Strategies for Profiting with Japanese Candlestick Charts
[http://bit.ly/2mGiZii] Investing with LEAPS: Choices in Long-Term Options
[http://bit.ly/2nTuPqs] Profitable Candlestick Trading: Pinpointing Market Opportunities to Maximize Profits
[http://bit.ly/2nHxJ2j] Trading for a Living: Psychology, Trading Tactics, Money Management
[http://bit.ly/2nbIQms] The New Trading for a Living: Psychology, Discipline, Trading Tools and Systems, Risk Control, Trade Management
[http://bit.ly/2miED0Z] Come Into My Trading Room: A Complete Guide to Trading
[http://bit.ly/2mX22Ag] The New Sell and Sell Short: How To Take Profits, Cut Losses, and Benefit From Price Declines by Wiley
[http://bit.ly/2nBlFD2] NeuroScience TravaCor, 120 capsules from NeuroScience
[http://bit.ly/2nBktj1] NootropX Advanced Nootropic Supplement
[http://bit.ly/2mK90cD] Alpha Brain By Onnit Labs
[http://bit.ly/2n536Wp] Pure Red Korean Panax Ginseng (1000mg Max Strength)
[http://bit.ly/2n4Zi7n] ULTRA Omega 3 Fish Oil 3,000mg High Strength 915mg EPA and 630 mg DHA
[http://bit.ly/2nbMPiK] How to Day Trade: A Detailed Guide to Day Trading Strategies
[http://bit.ly/2miy0eT] Death by China: Confronting the Dragon

Stock Market Crash 2017 Brewing

Before you dismiss this as just another gold/silver bug predicting gloom and doom so that they can profit, consider Caterpillar’s recent announcement that they are closing their Chicago plant and cutting 800 jobs along with it.

Caterpillar make’s large construction equipment and they’ve been struggling for a few years now. How can the companies that produce construction machines be going out of business when according to Janet Yellen the economy is getting stronger? Silver Report did a show discussing Caterpillar and the disconnect between soft data and hard data and makes some excellent points IMO.

Indicators of Stock Market Crash Brewing! Silver Price Economic Collapse 2017. Caterpillar Layoffs

Warning! Signs Of Withdrawal The Fed Effect On the Stock Market

It’s not being discussed much in the financial media about what the Fed said last week. The Fed said it would reduce its balance sheet and the previous plan was a reduction by 2021. What the Fed statement made clear last week is that the reduction of the Fed balance sheet will happen much sooner, starting in 2017. This was not something that was suppose to happen until 2018.

Now that troubling part is if you chart the Federal Reserve’s balance sheet with the S&P 500, it’s clear that the Fed was responsible for propping up the market and keeping this bull run going for some 8 years now. So when your 401k advisors show you a chart of the S&P 500 going up since the 2009 recession, what they aren’t showing you is that the upward move was largely from the Federal Reserve stepping in to the open markets and making large asset purchases. In other words, the stock market’s been on life-support all these years. You would get a completely different perspective of the bull rally since 2009 if you knew this one little important bit of information.

The danger is that most people are unaware that the Fed has been propping up the stock market for all these years. Most people think that the stock market has just been going up because the economy is getting stronger. Most people have no clue and have never seen the chart above. That’s a dangerous combination folks because when the Fed starts unwinding its $4.4 trillion balance sheet the stock market will likely go down and most amateur traders have no idea what’s coming.

Warning! Signs Of Withdrawal The Fed Effect On Stock Market, Economic Collapse 2017 and Silver

Sell Portola Pharmaceuticals For a 45% Win!

April 10, 2017: Sell Portola Pharmaceuticals for a 45% win and congratulations if you made money on the trade.

December 27, 2016: Portola Pharmaceuticals price target raised to $29 from $20 at Credit Suisse, reiterates Neutral rating.

December 26, 2016: Biotechnology firm Portola Pharmaceuticals had revenue of $12.1 million in 2015. For 2016, revenue is on track to more than double to $26.2 million.

December 23, 2016: Portola Pharmaceuticals reports that the FDA accepts NDA for priority review for betrixaban, a prophylaxis of venous thromboembolism (VTE) Granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six months from the standard review period of 10 months. The application for betrixaban, an FDA-designated Fast Track investigational drug, was deemed sufficiently complete to permit a substantive review and has been given a Prescription Drug User Fee Act (PDUFA) action date of June 24, 2017. Additionally, Portola announced that the European Medicines Agency (EMA) had validated its Marketing Authorization Application (MAA) for betrixaban for extended-duration prophylaxis of VTE in adults with acute medical illness and risk factors for VTE. The EMAs Committee for Medicinal Products for Human Use (CHMP) is reviewing the application under a standard 210-day review period.

December 19, 2016: Portola Pharmaceuticals announced it had signed a $50 million loan agreement with Bristol-Myers Squibb Company and Pfizer Inc. that provides additional funding toward development and clinical studies of AndexXa (andexanet alfa), an investigational compound that is a potential antidote for Factor Xa inhibitors. Under the terms of the agreement, Bristol-Myers Squibb and Pfizer will each loan Portola $25 million. The principal and interest will be repaid primarily through royalties on AndexXa commercial sales. No shares, warrants, options or other equity components were or will be issued in connection with the loan. The non-secured loan does not involve any transfer of patent ownership or licenses.

December 15, 2016: Heavy call activity detected in Portola Pharmaceuticals of 1500 Jan 20 calls traded at $1.15.

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases.